Literature DB >> 17889852

A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies.

Sabine Pellett1, William H Tepp, Colin M Clancy, Gary E Borodic, Eric A Johnson.   

Abstract

Clostridium botulinum neurotoxin (BoNT) serotypes A and B are widely used as pharmaceuticals to treat various neurological disorders and in cosmetic applications. The major adverse effect of these treatments has been resistance to treatment after multiple injections. Currently, patients receiving BoNT therapies and patients enrolled in clinical trials for new applications and/or new formulations of BoNTs are not routinely monitored for the formation of neutralizing antibodies, since no assay other than the mouse protection procedure is commercially available that reliably tests for the presence of such antibodies. This report presents a highly sensitive and specific neuronal cell-based assay that provides sensitive and specific detection of neutralizing antibodies to BoNT/A.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17889852      PMCID： PMC2748649          DOI： 10.1016/j.febslet.2007.08.078

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  37 in total

1.  Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences.

Authors:  H Göschel; K Wohlfarth; J Frevert; R Dengler; H Bigalke
Journal:  Exp Neurol       Date:  1997-09       Impact factor: 5.330

Review 2.  Botulinum toxin therapy, immunologic resistance, and problems with available materials.

Authors:  G Borodic; E Johnson; M Goodnough; E Schantz
Journal:  Neurology       Date:  1996-01       Impact factor: 9.910

Review 3.  The typing of botulinal neurotoxins.

Authors:  D F Giménez; J A Giménez
Journal:  Int J Food Microbiol       Date:  1995-09       Impact factor: 5.277

4.  Antibodies to botulinum toxin.

Authors:  G E Borodic; D Duane; B Pearce; E Johnson
Journal:  Neurology       Date:  1995-01       Impact factor: 9.910

5.  Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25.

Authors:  J Blasi; E R Chapman; E Link; T Binz; S Yamasaki; P De Camilli; T C Südhof; H Niemann; R Jahn
Journal:  Nature       Date:  1993-09-09       Impact factor: 49.962

6.  The EBD test--a clinical test for the detection of antibodies to botulinum toxin type A.

Authors:  K R Kessler; R Benecke
Journal:  Mov Disord       Date:  1997-01       Impact factor: 10.338

7.  Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin.

Authors:  S Yamasaki; A Baumeister; T Binz; J Blasi; E Link; F Cornille; B Roques; E M Fykse; T C Südhof; R Jahn
Journal:  J Biol Chem       Date:  1994-04-29       Impact factor: 5.157

8.  Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin.

Authors:  G Schiavo; C C Shone; O Rossetto; F C Alexander; C Montecucco
Journal:  J Biol Chem       Date:  1993-06-05       Impact factor: 5.157

Review 9.  Mechanism of action of tetanus and botulinum neurotoxins.

Authors:  C Montecucco; G Schiavo
Journal:  Mol Microbiol       Date:  1994-07       Impact factor: 3.501

10.  Botulinum neurotoxin type C cleaves a single Lys-Ala bond within the carboxyl-terminal region of syntaxins.

Authors:  G Schiavo; C C Shone; M K Bennett; R H Scheller; C Montecucco
Journal:  J Biol Chem       Date:  1995-05-05       Impact factor: 5.157
View more
  44 in total

1.  Neurotransmitter vesicle release from human model neurons (NT2) is sensitive to botulinum toxin A.

Authors:  Million Adane Tegenge; Helge Böhnel; Frank Gessler; Gerd Bicker
Journal:  Cell Mol Neurobiol       Date:  2012-02-29       Impact factor: 5.046

2.  Neuronal targeting, internalization, and biological activity of a recombinant atoxic derivative of botulinum neurotoxin A.

Authors:  Sabine Pellett; William H Tepp; Larry H Stanker; Philip A Band; Eric A Johnson; Konstantin Ichtchenko
Journal:  Biochem Biophys Res Commun       Date:  2011-02-01       Impact factor: 3.575

3.  Bimodal modulation of the botulinum neurotoxin protein-conducting channel.

Authors:  Audrey Fischer; Yuya Nakai; Lisa M Eubanks; Colin M Clancy; William H Tepp; Sabine Pellett; Tobin J Dickerson; Eric A Johnson; Kim D Janda; Mauricio Montal
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-21       Impact factor: 11.205

4.  Targeting botulinum A cellular toxicity: a prodrug approach.

Authors:  Peter Silhár; Lisa M Eubanks; Hajime Seki; Sabine Pellett; Sacha Javor; William H Tepp; Eric A Johnson; Kim D Janda
Journal:  J Med Chem       Date:  2013-10-15       Impact factor: 7.446

5.  Activity of botulinum neurotoxin type D (strain 1873) in human neurons.

Authors:  Sabine Pellett; William H Tepp; Jacob M Scherf; Christina L Pier; Eric A Johnson
Journal:  Toxicon       Date:  2015-04-30       Impact factor: 3.033

6.  Enhancing toxin-based vaccines against botulism.

Authors:  Amanda Przedpelski; William H Tepp; Madison Zuverink; Eric A Johnson; Sabine Pellet; Joseph T Barbieri
Journal:  Vaccine       Date:  2018-01-04       Impact factor: 3.641

7.  A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin.

Authors:  Susan E Maslanka; Carolina Lúquez; Janet K Dykes; William H Tepp; Christina L Pier; Sabine Pellett; Brian H Raphael; Suzanne R Kalb; John R Barr; Agam Rao; Eric A Johnson
Journal:  J Infect Dis       Date:  2015-06-10       Impact factor: 5.226

Review 8.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

9.  New approach for the rational selection of markers to identify botulinum toxins.

Authors:  Osnat Rosen; Liron Feldberg; Eyal Dor; Ran Zichel
Journal:  Arch Toxicol       Date:  2021-02-10       Impact factor: 5.153

Review 10.  Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery.

Authors:  Erkan Kiris; Krishna P Kota; James C Burnett; Veronica Soloveva; Christopher D Kane; Sina Bavari
Journal:  Expert Rev Mol Diagn       Date:  2014-01-23       Impact factor: 5.225
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.